Physician profile
Donna Mathis
NPI 1467454413
$2,278.02
in general payments reported to CMS, 2019-2025
36 companies · $509 in 2025
The $509 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $458 · 2022: $363 · 2023: $435 · 2024: $513 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $594.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $429.65 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $150.51 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Pfizer INC. | $111.72 | 2021-2023 | |
| Amgen INC. | $101.02 | 2022-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $91.17 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $79.26 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $56.95 | 2023 | Rytary |
| Mylan Specialty L.P. | $56.75 | 2021-2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company Ltd. | $53.81 | 2022 | |
| Boston Scientific Corporation | $47.54 | 2024 | Watchman Access System, Wavewriter Alpha Prime 16 |
| Otsuka America Pharmaceutical, INC. | $43.88 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $37.02 | 2025 | |
| Axsome Therapeutics, INC. | $30.23 | 2024 | Auvelity |
| Novo Nordisk INC | $30.18 | 2022-2025 | Rybelsus, Ozempic |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $28.19 | 2021 | |
| Supernus Pharmaceuticals, INC. | $25.52 | 2021 | |
| Astellas Pharma US INC | $21.26 | 2024 | Veozah |
| Collegium Pharmaceutical, INC. | $19.57 | 2023 | Xtampza |
| Sanofi Pasteur INC. | $19.28 | 2025 | |
| Abbott Laboratories | $18.68 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $18.09 | 2022 | |
| Sumitomo Pharma America, INC. | $17.82 | 2025 | Gemtesa |
| Organon LLC | $17.56 | 2022 | |
| Harmony Biosciences LLC | $17.20 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.99 | 2025 | Zoryve |
| Xeris Pharmaceuticals, INC. | $15.79 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.70 | 2025 | Eliquis |
| Antares Pharma, INC. | $15.54 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.22 | 2023 | Tradjenta |
| Phathom Pharmaceuticals, INC. | $15.21 | 2024 | Voquezna |
| Indivior INC. | $14.59 | 2024 | Sublocade |
| Sanofi-Aventis U.S. LLC | $13.79 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.74 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $13.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.